With the Clinical Trials in Inherited Ataxias (CTAX) conference workshop coming to a close, NAF followed it up with an appearance at Euro-ataxia’s International Ataxia Patient Conference. The meeting was made up of Ataxia patient advocacy organizations, as well as select clinical researchers and industry and patient representatives, from across Europe and other parts of the world.
Discussions were held about the ways each group is working to accelerate drug development and expand access to therapies for Ataxia. There was an additional focus on areas for collaboration between organizations to support patient-centered drug development. Our CEO Andrew Rosen spoke about NAF’s Drug Development Collaborative. NAF is proud to contribute to growing international efforts in the pursuit of a world without Ataxia.
